2018: A banner year for hematology drug approvalsDecember 5, 2018Business of MedicineCLLAggressive LymphomasMixed Topics
Phase 3 study confirms biosimilarity of PF-05280586 with rituximabDecember 5, 2018Aggressive LymphomasB Cell Lymphoma
Factor IX expression stable at up to 8 years with gene therapyDecember 5, 2018Bleeding DisordersGene Therapy
CLL resistance mechanism to venetoclax identifiedDecember 5, 2018CLLAggressive LymphomasB Cell Lymphoma
Large cohort study IDs prognostic factors in thromboangiitis obliteransDecember 5, 2018Mixed TopicsThrombosis
Shorter R-CHOP regimen noninferior in certain DLBCL patientsDecember 5, 2018Non-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma